Alyssa M Peckham1, Kathleen A Fairman2, David A Sclar2. 1. Department of Pharmacy Practice, College of Pharmacy-Glendale, Midwestern University, 19555 N. 59th Avenue, Glendale, AZ, 85308, USA. apeckh@midwestern.edu. 2. Department of Pharmacy Practice, College of Pharmacy-Glendale, Midwestern University, 19555 N. 59th Avenue, Glendale, AZ, 85308, USA.
Abstract
BACKGROUND: Despite international calls to make gabapentin a controlled substance, studies of gabapentin use/abuse patterns are limited to small/high-risk samples and adverse event reports. OBJECTIVE: The aim of this study was to conduct a systematic assessment of the abuse potential/prevalence of gabapentin in a large sample. DATA SOURCE: Truven Health MarketScan® Commercial Claims and Encounters database, years 2013-2015. ELIGIBILITY CRITERIA: Patients with two or more claims for one or more abusable drugs and ≥12 months' continuous enrollment were sampled for Lorenz curve analysis. Prevalence analysis was limited to those with ≥120 days of therapy. METHODS: Abuse potential was measured as Lorenz-1 (consumption of drug supply by top 1% of users) of ≥15%. Dose thresholds were morphine milligram equivalent (MME) standards for opioids, and maximum labeled doses in milligrams (mg) for other drugs. RESULTS: Lorenz-1 values were 37% opioids, 19% gabapentin, 15% pregabalin, 14% alprazolam, and 13% zolpidem. The top 1% gabapentin users filled prescriptions for a mean (median) 11,274 (9534) mg/day, more than three times the recommended maximum (3600 mg). Of these, one-quarter used or diverted ≥12,822 mg/day. The top 1% opioid and pregabalin users filled prescriptions for a mean (median) 180 (127) MMEs and 2474 (2219) mg/day, respectively. Of patients using opioids + gabapentin simultaneously, 24% had three or more claims exceeding the dose threshold within 12 months. LIMITATIONS: Established threshold criteria for gabapentinoid abuse are uncertain. Indications for gabapentinoid use (e.g. hot flashes, restless legs syndrome) were not measured. CONCLUSION: Gabapentin use patterns are similar to those of other abusable medications. High daily doses pose safety and/or diversion concerns, and investigation of the medical consequences of gabapentin abuse is needed.
BACKGROUND: Despite international calls to make gabapentin a controlled substance, studies of gabapentin use/abuse patterns are limited to small/high-risk samples and adverse event reports. OBJECTIVE: The aim of this study was to conduct a systematic assessment of the abuse potential/prevalence of gabapentin in a large sample. DATA SOURCE: Truven Health MarketScan® Commercial Claims and Encounters database, years 2013-2015. ELIGIBILITY CRITERIA: Patients with two or more claims for one or more abusable drugs and ≥12 months' continuous enrollment were sampled for Lorenz curve analysis. Prevalence analysis was limited to those with ≥120 days of therapy. METHODS: Abuse potential was measured as Lorenz-1 (consumption of drug supply by top 1% of users) of ≥15%. Dose thresholds were morphine milligram equivalent (MME) standards for opioids, and maximum labeled doses in milligrams (mg) for other drugs. RESULTS: Lorenz-1 values were 37% opioids, 19% gabapentin, 15% pregabalin, 14% alprazolam, and 13% zolpidem. The top 1% gabapentin users filled prescriptions for a mean (median) 11,274 (9534) mg/day, more than three times the recommended maximum (3600 mg). Of these, one-quarter used or diverted ≥12,822 mg/day. The top 1% opioid and pregabalin users filled prescriptions for a mean (median) 180 (127) MMEs and 2474 (2219) mg/day, respectively. Of patients using opioids + gabapentin simultaneously, 24% had three or more claims exceeding the dose threshold within 12 months. LIMITATIONS: Established threshold criteria for gabapentinoid abuse are uncertain. Indications for gabapentinoid use (e.g. hot flashes, restless legs syndrome) were not measured. CONCLUSION: Gabapentin use patterns are similar to those of other abusable medications. High daily doses pose safety and/or diversion concerns, and investigation of the medical consequences of gabapentin abuse is needed.
Authors: Lin Xie; Ashish V Joshi; David Schaaf; Jack Mardekian; James Harnett; Nilay D Shah; Onur Baser Journal: Pain Pract Date: 2013-06-30 Impact factor: 3.183
Authors: Noam Y Kirson; Lauren M Scarpati; Caroline J Enloe; Aliya P Dincer; Howard G Birnbaum; Tracy J Mayne Journal: J Manag Care Spec Pharm Date: 2016-12-30
Authors: Thitiporn Supasitthumrong; Blanca M Bolea-Alamanac; Selim Asmer; Vincent L Woo; Petal S Abdool; Simon J C Davies Journal: Br J Clin Pharmacol Date: 2019-02-08 Impact factor: 4.335
Authors: Elizabeth A Ibiloye; Jamie C Barner; Kenneth A Lawson; Karen L Rascati; Kirk E Evoy; Alyssa M Peckham Journal: Clin Drug Investig Date: 2021-02-12 Impact factor: 2.859
Authors: Jessica I Billig; Erika D Sears; Vidhya Gunaseelan; Katherine B Santosa; Theodore J Iwashyna; Michael J Englesbe; Chad M Brummett; Jennifer F Waljee Journal: J Hand Surg Am Date: 2020-05-30 Impact factor: 2.230
Authors: Lili Zhou; Sandipan Bhattacharjee; C Kent Kwoh; Patrick J Tighe; Gary M Reisfield; Daniel C Malone; Marion Slack; Debbie L Wilson; Ching-Yuan Chang; Wei-Hsuan Lo-Ciganic Journal: Addiction Date: 2020-08-19 Impact factor: 6.526
Authors: Emil Isagulyan; Konstantin Slavin; Nikolay Konovalov; Eugeny Dorochov; Alexey Tomsky; Andrey Dekopov; Elizaveta Makashova; David Isagulyan; Pavel Genov Journal: Korean J Pain Date: 2020-04-01